ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Immuno-Oncology: Current Market Landscape and Future Trends（2） Neeta Ratanghayra
September 18, 2024CAR-T Therapy & Antibody–Drug Conjugates. -
Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData expresspharma
April 23, 2021Class-wide sales of IO are expected to grow to 72.2 per cent of the market, contributing $3.8 billion to global sales in 2029 and growing at a CAGR of 28 per cent. -
Doctors keen to adopt novel biomarkers for immuno-oncology regimens: GlobalData expresspharma
March 16, 2021The most promising or anticipated biomarker among high-prescribing physicians in the seven major markets was identified to be measures of tumour mutational burden. -
Zydus, XOMA Enter IO Agreement contractpharma
March 10, 2020To advance an IL-2-based immuno-oncology drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody. -
Pfizer’s new partnership focuses on digitising clinical trials pharmaceutical-technology
February 21, 2019Pfizer has partnered with non-profit healthcare system Ochsner Health System to develop digital models that aim to improve clinical trials..... -
Astellas Pharma Acquires Potenza Therapeutics
contractpharma
December 18, 2018Astellas Pharma Inc.?has exercised its exclusive option to acquire?Potenza Therapeutics, Inc., paying $164.6 million?upfront and additional payments of as much as $240.1?million, depending on the progress of various programs.
Pharma Sources Insight January 2025
